Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors increased its Keros Therapeutics stake by 453.9% in the first quarter, purchasing 263,347 additional shares and bringing its ownership to 321,360 shares, or about 1.62% of the company. Institutional investors and hedge funds collectively own 71.56% of KROS.
• Keros shares opened at $11.20, up 5.3%, but the company reported a quarterly loss of $1.45 per share, missing analyst expectations of a $1.34 loss. The stock remains well below its 52-week high of $22.55.
• Analyst sentiment is mixed: the stock has a consensus “Hold” rating and a $20.50 target price, while recent reports included a Buy reiteration and several downgrades. Meanwhile, insiders sold 8,425 shares worth nearly $90,000 over the past 90 days.

Dimensional Fund Advisors LP lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 453.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 321,360 shares of the company's stock after buying an additional 263,347 shares during the period. Dimensional Fund Advisors LP owned approximately 1.62% of Keros Therapeutics worth $3,547,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Financial Management Professionals Inc. acquired a new stake in Keros Therapeutics in the 4th quarter valued at about $29,000. Caitong International Asset Management Co. Ltd lifted its stake in Keros Therapeutics by 254.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company's stock worth $33,000 after purchasing an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock worth $42,000 after purchasing an additional 1,888 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Keros Therapeutics by 264.1% during the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company's stock worth $142,000 after purchasing an additional 7,700 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Keros Therapeutics by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company's stock valued at $166,000 after purchasing an additional 988 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Julius Knowles sold 2,625 shares of the business's stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director directly owned 10,958 shares of the company's stock, valued at approximately $117,579.34. The trade was a 19.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the business's stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.72, for a total transaction of $28,140.00. Following the completion of the sale, the director directly owned 9,767 shares in the company, valued at $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,425 shares of company stock valued at $89,994 over the last 90 days. 12.60% of the stock is owned by insiders.

Keros Therapeutics Stock Up 5.3%

Shares of Keros Therapeutics stock opened at $11.20 on Thursday. Keros Therapeutics, Inc. has a 52 week low of $9.69 and a 52 week high of $22.55. The business's fifty day simple moving average is $10.63 and its 200-day simple moving average is $12.17. The firm has a market cap of $222.10 million, a PE ratio of -3.03 and a beta of 0.99.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, equities analysts expect that Keros Therapeutics, Inc. will post -5.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

KROS has been the subject of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Leerink Partners lowered their price target on shares of Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 4th. Wall Street Zen raised shares of Keros Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, August 8th. Zacks Research downgraded shares of Keros Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Wednesday, July 29th. Finally, Weiss Ratings downgraded shares of Keros Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Friday, May 15th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $20.50.

Keros Therapeutics Profile

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source